Genentech, Foundation Medicine Patent EP3523451A1, Cancer Treatment Methods
Summary
European patent application EP3523451A1 published April 15, 2026, listing Genentech, Inc. and Foundation Medicine, Inc. as joint applicants for therapeutic and diagnostic methods in cancer (A61P 35/00). Nine named inventors are credited across immuno-oncology and companion diagnostics. IPC classifications include C12Q, A61K, A61P, and C07K 16/28.
About this source
GovPing monitors EPO Patent Bulletin - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 17 changes logged to date.
What changed
The EPO published patent application EP3523451A1 designating all European member states, covering therapeutic and diagnostic methods for cancer including antibodies (C07K 16/28), immunological compositions (A61K 39/395), and companion diagnostics (C12Q 1/68). Nine inventors are listed across oncology, genomics, and immunology fields. This publication makes the application's claims publicly available for examination and opposition purposes.
Competitors in immuno-oncology and cancer diagnostics should review the published claims to assess freedom-to-operate implications. Research institutions and biotech firms developing PD-L1/PD-1 targeted therapies or genomic companion diagnostics may find overlapping claim scope requiring prior art review or licensing discussions with Genentech and Foundation Medicine.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
THERAPEUTIC AND DIAGNOSTIC METHODS FOR CANCER
Publication EP3523451A1 Kind: A1 Apr 15, 2026
Applicants
Genentech, Inc., Foundation Medicine, Inc.
Inventors
SHAMES, David, FABRIZIO, David, FRAMPTON, Garrett, M., HEGDE, Priti, KOWANETZ, Marcin, STEPHENS, Philip, J., SUN, James, Xin, YELENSKY, Roman, ZOU, Wei
IPC Classifications
C12Q 1/68 20180101AFI20180413BHEP A61K 39/395 20060101ALI20180413BHEP A61P 35/00 20060101ALI20180413BHEP C07K 16/28 20060101ALI20180413BHEP
Designated States
AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR
Related changes
Get daily alerts for EPO Patent Bulletin - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from EPO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when EPO Patent Bulletin - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.